Skip to main content
. Author manuscript; available in PMC: 2008 Sep 3.
Published in final edited form as: Diabetes. 2007 Mar 15;56(6):1680–1685. doi: 10.2337/db07-0009

TABLE 3.

Cox regression models estimating hazard ratios for change in body fat measurement (year 1 minus baseline) in predicting diabetes by treatment group and sex*

Placebo
Metformin
Lifestyle intervention
Baseline minus year 1 R2 HR (95% CI) P value R2 HR (95% CI) P value R2 HR (95% CI) P value
Men
  Visceral L2-L3 (cm2) 3.9 0.54 (0.27–1.09) 0.08 0.2 0.86 (0.45–1.66) 0.65 10.4 0.16 (0.03–0.81) 0.03
  Visceral L4-L5 (cm2) 1.3 0.71 (0.38–1.35) 0.30 0.0 0.97 (0.50–1.90) 0.94 10.5 0.13 (0.03–0.63) 0.01
  Subcutaneous L2-L3 (cm2) 13.4 0.37 (0.19–0.71) <0.01 0.2 0.90 (0.52–1.55) 0.70 8.5 0.18 (0.04–0.81) 0.03
  Subcutaneous L4-L5 (cm2) 10.0 0.40 (0.19–0.82) 0.01 0.5 1.28 (0.66–2.51) 0.47 10.4 0.15 (0.03–0.65) 0.01
  Weight (kg) 3.4 0.61 (0.33–1.13) 0.11 0.6 1.36 (0.64–2.88) 0.42 9.3 0.22 (0.06–0.78) 0.02
  Waist (cm) 2.3 0.67 (0.36–1.26) 0.19 0.5 1.38 (0.64–2.95) 0.50 12.7 0.19 (0.05–0.72) 0.02
  BMI (kg/m2) 2.1 0.65 (0.34–1.23) 0.22 0.7 1.33 (0.58–3.05) 0.41 9.9 0.10 (0.01–0.75) 0.01
  WHR (cm) 0.0 1.03 (0.58–1.84) 0.92 0.3 1.21 (0.59–2.50) 0.60 5.9 0.22 (0.05–1.08) 0.06
Women
  Visceral L2-L3 (cm2) 0.7 0.77 (0.47–1.26) 0.30 0.0 1.09 (0.62–1.90) 0.77 2.2 0.71 (0.49–1.03) 0.07
  Visceral L4-L5 (cm2) 0.6 0.77 (0.48–1.26) 0.30 1.5 0.66 (0.39–1.09) 0.10 2.3 0.71 (0.50–1.02) 0.06
  Subcutaneous L2-L3 (cm2) 1.0 0.71 (0.40–1.25) 0.23 0.0 0.93 (0.56–1.56) 0.79 0.7 0.81 (0.58–1.15) 0.25
  Subcutaneous L4-L5 (cm2) 1.3 0.72 (0.46–1.12) 0.15 0.5 0.79 (0.49–1.29) 0.35 1.5 0.68 (0.41–1.14) 0.14
  Weight (kg) 1.2 0.66 (0.38–1.14) 0.14 0.6 0.75 (0.43–1.32) 0.31 6.0 0.40 (0.21–0.74) <0.01
  Waist (cm) 0.6 0.68 (0.40–1.17) 0.26 0.0 0.76 (0.43–1.34) 0.99 3.5 0.41 (0.22–0.74) 0.02
  BMI (kg/m2) 1.0 0.74 (0.44–1.24) 0.17 0.6 1.00 (0.59–1.70) 0.35 6.4 0.50 (0.28–0.90) <0.01
  WHR (cm) 0.2 0.87 (0.59–1.29) 0.50 0.0 1.02 (0.63–1.65) 0.93 0.0 1.03 (0.65–1.64) 0.90
*

R2 are treatment group specific and measure the percent of variation explained when the body fat measurement is added to a model with baseline body fat, age, and self-reported race/ethnicity as independent variables. Hazard ratios (HRs) are per 1 SD

Significant differences between treatment groups.